Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …

Background Historically, warfarin or aspirin have been the recommended therapeutic
options for the extended treatment (> 3 months) of VTE. Data from Phase III randomised …

Objectives The aim was to perform a review of the efficacy and safety of new oral
anticoagulants (NOAs) in the management of venous thromboembolism (VTE). Methods …

Essentials• We investigated direct oral anticoagulant (DOAC) use in venous
thromboembolism and thrombophilia.• A comprehensive search identified 10 studies, 8 of …

Abstract Background Direct oral anticoagulants (DOACs), namely rivaroxaban, apixaban,
dabigatran, and edoxaban, are now included together with warfarin as standards of care for …

What is known and objective: Dabigatran and rivaroxaban are new oral anticoagulants for
thromboprophylaxis after elective orthopaedic surgery. We aimed to systematically compare …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

Background Numerous new oral anticoagulants (NOACs) have been compared to a
parenteral anticoagulant/oral vitamin K antagonist (VKA) for the treatment of acute venous …

The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban,
and edoxaban, are poised to replace warfarin for treatment of the majority of patients with …

Thromboembolic disorders are among the major causes of morbidity and mortality, and
anticoagulation remains the cornerstone of prevention and treatment of these disorders …